AstraZeneca said it is launching a new fund with China International Capital Corporation (CICC) to invest $1 billion in China’s healthcare sector, as it expands its research work in the country.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
